Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the ...

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Stoke Therapeutics (STOK – Research Report), Novavax (NVAX – Research Report) ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

Good morning and welcome to Novavax First Quarter 2025 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.